Search

Displaying results 4071 - 4080 of 10000 in total
  1. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  2. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  3. Drug

    Levilimab

    go.drugbank.com/drugs/DB16387
    Investigational

    Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).

  4. Drug

    Viral Macrophage-Inflammatory Protein

    go.drugbank.com/drugs/DB15748
    Experimental

    The structure of vMIP consists of 71 residues and is a monomer under most conditions. … Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8.

  5. Drug

    Becocalcidiol

    go.drugbank.com/drugs/DB04891
    Investigational

    Becocalcidiol is a vitamin D(3) analogue which has not caused hypercalcaemia or significant irritation in preclinical trials.

  6. Drug

    VGA039

    go.drugbank.com/drugs/DB18385
    Investigational

    VGA039 is an IgG4 monoclonal antibody directed against protein S.

  7. Drug

    Aminomethylbenzoic acid

    go.drugbank.com/drugs/DB13244
    Experimental

    Aminomethylbenzoic acid may be useful as an antifibrinolytic agent [A174994].

  8. Drug

    AMG 108

    go.drugbank.com/drugs/DB05545
    Investigational

    AMG 108 was investigated for use as an antirheumatic agent.

  9. Drug

    Troxacitabine

    go.drugbank.com/drugs/DB04961
    Investigational

    Troxacitabine is a nucleoside analog with antineoplastic activity. There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.

  10. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines.